ER-positive and PR-positive cases have a lower risk of mortality than ER-negative and/or PR-negative cases, while HER2-positive breast cancers tend to be more aggressive and have a poorer prognosis than HER2-negative breast cancer [1, 2]. This evidence concerns the gene ERBB2 and breast carcinoma.